JP7731344B2 - デング熱及びa型肝炎を予防するための方法 - Google Patents

デング熱及びa型肝炎を予防するための方法

Info

Publication number
JP7731344B2
JP7731344B2 JP2022509723A JP2022509723A JP7731344B2 JP 7731344 B2 JP7731344 B2 JP 7731344B2 JP 2022509723 A JP2022509723 A JP 2022509723A JP 2022509723 A JP2022509723 A JP 2022509723A JP 7731344 B2 JP7731344 B2 JP 7731344B2
Authority
JP
Japan
Prior art keywords
dengue
serotype
vaccine
hepatitis
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544613A (ja
JP2022544613A5 (cg-RX-API-DMAC7.html
Inventor
ウォレス、デレック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/561,953 external-priority patent/US11590221B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of JP2022544613A publication Critical patent/JP2022544613A/ja
Publication of JP2022544613A5 publication Critical patent/JP2022544613A5/ja
Priority to JP2024177535A priority Critical patent/JP2025032070A/ja
Application granted granted Critical
Publication of JP7731344B2 publication Critical patent/JP7731344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022509723A 2019-08-16 2020-03-04 デング熱及びa型肝炎を予防するための方法 Active JP7731344B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177535A JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
IDP00201907241 2019-08-16
IDPID2019-07241 2019-08-16
EP19195692.9 2019-09-05
USPCT/US2019/049749 2019-09-05
US16/561,953 US11590221B2 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
EP19195692.9A EP3620174B1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
PCT/US2019/049749 WO2020051334A1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
US16/561,953 2019-09-05
PCT/US2020/020991 WO2021034349A1 (en) 2019-08-16 2020-03-04 Methods for preventing dengue and hepatitis a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177535A Division JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Publications (3)

Publication Number Publication Date
JP2022544613A JP2022544613A (ja) 2022-10-19
JP2022544613A5 JP2022544613A5 (cg-RX-API-DMAC7.html) 2023-03-09
JP7731344B2 true JP7731344B2 (ja) 2025-08-29

Family

ID=74660757

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509723A Active JP7731344B2 (ja) 2019-08-16 2020-03-04 デング熱及びa型肝炎を予防するための方法
JP2024177535A Pending JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177535A Pending JP2025032070A (ja) 2019-08-16 2024-10-09 デング熱及びa型肝炎を予防するための方法

Country Status (10)

Country Link
EP (1) EP4013451A1 (cg-RX-API-DMAC7.html)
JP (2) JP7731344B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220049023A (cg-RX-API-DMAC7.html)
CN (1) CN114555113A (cg-RX-API-DMAC7.html)
AU (3) AU2020331884B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147807A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022001742A (cg-RX-API-DMAC7.html)
PH (1) PH12022550261A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021034349A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260167703A1 (en) * 2022-11-02 2026-06-18 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
DK2054428T3 (da) 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) * 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Bock, H. L. et al.,Does the concurrent administration of an inactivated hepatitis A vaccine influence the immune response to other travelers vaccines?, Journal of Travel Medicine,2000年,Vol.7, No.2,p.74-78,doi:10.2310/7060.2000.00025
History of Changes for Study: NCT03525119,ClinicalTrials.gov archive [online],2018年05月03日,[検索日 2024.03.28], Retrieved from the Internet: <https://classic.clinicaltrials.gov/ct2/history/NCT03525119?V_1>
Osorio, J. E. et al.,Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques,The American Journal of Tropical Medicine and Hygiene,2011年,Vol.84, No.6,p.978-987,doi:10.4269/ajtmh.2011.10-0592
Rinderknecht, S. et al.,Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age,The Pediatric Infectious Disease Journal,2011年,Vol.30, No.10,p.e179-e185,doi:10.1097/INF.0b013e31822256a5
Saez-Llorens, X. et al.,Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study,The Lancet. Infectious Diseases,2017年,Vol.17, No.6,p.615-625,doi:10.1016/S1473-3099(17)30166-4
Sridhar, S. et al.,Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy,The New England Journal of Medicine,2018年07月26日,Vol.379, No.4,p.327-340,doi:10.1056/NEJMoa1800820

Also Published As

Publication number Publication date
AU2026202847A1 (en) 2026-05-07
WO2021034349A1 (en) 2021-02-25
JP2022544613A (ja) 2022-10-19
JP2025032070A (ja) 2025-03-11
AU2020331884B2 (en) 2025-01-23
KR20220049023A (ko) 2022-04-20
PH12022550261A1 (en) 2023-06-26
AU2025202876B2 (en) 2026-01-29
MX2022001742A (es) 2022-04-07
EP4013451A1 (en) 2022-06-22
CN114555113A (zh) 2022-05-27
BR112022001476A2 (pt) 2023-10-03
CA3147807A1 (en) 2021-02-25
AU2020331884A1 (en) 2022-03-03
AU2025202876A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
JP7791925B2 (ja) デング熱ワクチン単位用量及びその投与
US10946087B2 (en) Vaccine compositions against dengue virus diseases
US20230233628A1 (en) Dengue vaccine unit dose and administration thereof
AU2026202847A1 (en) Methods For Preventing Dengue And Yellow Fever
US12201683B2 (en) Methods for preventing dengue and hepatitis a
WO2025072259A9 (en) Coadministration of tetravalent dengue vaccine with hpv vaccine
HK40082761A (en) Dengue vaccine unit dose and administration thereof
HK40023196A (en) Dengue vaccine unit dose and administration thereof
HK40023196B (en) Dengue vaccine unit dose and administration thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220413

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250819

R150 Certificate of patent or registration of utility model

Ref document number: 7731344

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150